No Data
Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com
Research Alert: CFRA Keeps Buy View On Shares Of Merck & Co., Inc.
Merck Lowers Full-Year Earnings Outlook Despite First-Quarter Beat
Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk
Express News | Merck Exec Says Co Securing Additional Manufacturing in the U.S. for Keytruda Through Contract Manufacturers, Internal Manufacturing - Conf Call
Express News | Merck Exec Says Co Has on Hand Inventory in the United States to Manage Tariff Impact on Keytruda Through 2025 - Conf Call